Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

被引:0
|
作者
E. Espinosa
S. Morales
P. Borrega
A. Casas
C. Madroñal
I. Machengs
J. A. Illarramendi
J. Lizón
J. A. Moreno
J. Belón
J. Janáriz
M. de la Puente
T. Checa
J. R. Mel
M. González Barón
机构
[1] Oncopaz Cooperative Group,Servicio de Oncología Médica
[2] Hospital La Paz,undefined
来源
关键词
Locally advanced breast cancer; Epirubicin; High-dose; Docetaxel; Neoadjuvant;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:546 / 552
页数:6
相关论文
共 50 条
  • [1] Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
    Espinosa, E
    Morales, S
    Borrega, P
    Casas, A
    Madroñal, C
    Machengs, I
    Illarramendi, J
    Lizón, J
    Moreno, J
    Belón, J
    Janáriz, J
    de la Puente, M
    Checa, T
    Mel, JR
    Barón, MG
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (06) : 546 - 552
  • [2] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [3] The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer
    Hirano, A
    Shimizu, T
    Imamura, H
    Watanabe, O
    Kinoshita, J
    Okabe, T
    Kimura, K
    Kamimura, M
    Domoto, K
    Aiba, M
    Ogawa, K
    [J]. ANTICANCER RESEARCH, 2006, 26 (1B) : 581 - 584
  • [4] Induction preoperative chemotherapy with high-dose epirubicin in locally advanced breast cancer (LABC)
    Silvestro, P
    DAiuto, G
    Caparrotti, G
    Menditto, C
    Tambaro, R
    Rinaldi, L
    Pergola, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 713 - 713
  • [5] Epirubicin and Docetaxel as Primary Chemotherapy in Locally Advanced Breast Cancer
    Conti, F.
    Corsetti, S.
    Viola, G.
    Sperduti, I.
    Carpano, S.
    Pizzuti, L.
    Foggi, P.
    Perri, P.
    Anza, M.
    Toglia, G.
    Lopez, M.
    [J]. ONCOLOGY, 2009, 77 : 139 - 140
  • [6] Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
    Won, Hye Sung
    Kim, Yong Seok
    Kim, Jeong Soo
    Chang, Eun Deok
    Na, Sae Jung
    Whang, In Yong
    Lee, Dong Soo
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (06): : 1489 - 1496
  • [7] Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
    Puerto, VL
    Cardenas, J
    Lara, F
    Goana, R
    Silva, A
    Barroso, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 299 - 299
  • [8] High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study.
    Milla, A
    Morales, S
    Burillo, MA
    Borrega, P
    Machenes, I
    Checa, T
    Janariz, J
    Illaramendi, JJ
    Lizon, J
    Gonzalez-Baron, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
  • [9] Dose finding study of high-dose epirubicin (E) and docetaxel (T) as first line chemotherapy in advanced breast cancer (ABC)
    Pagani, O
    Aapro, M
    Martinelli, G
    Bauer, J
    Borner, M
    Crivellari, D
    Thurlimann, B
    Vandenbulcke, T
    Goldhirsch, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 654 - 654
  • [10] A phase II trial of docetaxel (taxotere) in combination with epirubicin as neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Fried, G
    Zidan, J
    Epelbaum, R
    Keren-Rosenberg, S
    Basher, W
    Steckelman, I
    Kogan, F
    Haim, N
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S69 - S70